TheraSci

TheraSci was a biopharmaceutical company primarily focused on the discovery and development of novel small molecule therapeutics for metabolic diseases, including type 2 diabetes and obesity. The company's research programs targeted key metabolic regulators such as PPAR-gamma and PTP1B to improve insulin sensitivity and glucose homeostasis. Founded in the late 1990s, TheraSci established a pipeline of preclinical candidates aimed at addressing the growing global burden of metabolic syndrome. The company was strategically acquired by Metabolex (now CymaBay Therapeutics) in 2000 to consolidate expertise and assets in the metabolic disease space.